Doxorubicin-eluting beads - BTG
Alternative Names: DC Bead; DC Bead LUMI™; DEBDOX; Doxorubicin-loaded DC Bead LUMI™; E7040; Embolic bead; LifePearl; PRECISION BeadLatest Information Update: 14 Jan 2022
At a glance
- Originator Biocompatibles International; Eisai Co Ltd
- Developer Biocompatibles International; BTG; Eisai Co Ltd; SciClone Pharmaceuticals; Terumo
- Class Anthracyclines; Antineoplastics; Cytostatic antibiotics; Doxorubicins; Small molecules
- Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Liver cancer; Vascular disorders
- No development reported Lung cancer
Most Recent Events
- 19 Aug 2019 BTG has been acquired by Boston Scientific Corporation
- 12 Mar 2018 BTG and Biocompatabilities International plans a clinical trial for Hepatocellular carcinoma in April 2018 (NCT03452553)
- 01 Mar 2017 No development reported - Phase-II for liver cancer in USA (Intra-arterial)